March 10th, 2021 | 09:27 CET
BioNTech, CureVac, Cardiol Therapeutics: Biotech rockets off the launchpad
Table of contents:
At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.
BioNTech: What's next for the vaccine hopeful?
The BioNTech share was an investor favorite for many months. Even today, the stock still has a lot to offer fundamentally. The Company is a leader in mRNA technology and was the first to develop a vaccine against Covid-19 successfully. Currently, it shows that it has paid off to break new ground in vaccine development. BioNTech's preparation is extremely effective and, almost more importantly, can interrupt chains of infection. One of the reasons why more and more experts are now advocating that younger people should also be vaccinated with BioNTech. If people with many contacts are vaccinated with it, it can have a significant epidemiological effect, they believe.
In the stock market, the stock has lost about 27% in the past three months. Given the increase in the preceding months, this is not a significant blow, but momentum seems to have left the share. It is currently rather unlikely that the share will rush from one high to the next as it did in the fall. Even if BioNTech is an excellent company, the share is currently lacking esprit.
CureVac: Share does not gain momentum
Similar to BioNTech, the Tübingen-based competitor CureVac is also suffering. The Company has also focused on mRNA technology and has developed an effective vaccine currently undergoing approval procedures within the EU. A partner for the production of the vaccine has also been found in Novartis. Together, the two companies plan to bring 50 million doses to market this year. In 2022, the aim is to produce a further 200 million vaccine doses. On a three-month view, however, CureVac's stock is underperforming BioNTech, losing about 37%. It seems that once the first vaccines are ready for the market, the fantasy around the share fades.
Cardiol Therapeutics: Story and valuation are right here
Nevertheless, Covid-19 and its mutations will be with us for many years to come. The vaccine manufacturers mentioned above will also adapt their preparations and bring new versions to market. It is similar to what is already happening with flu vaccines. In the future, one focus is also likely to be on mitigating severe courses or successfully treating patients with various pre-existing conditions. The biotech Company Cardiol Therapeutics is developing its active ingredient CardiolRx™ to treat inflammatory heart disease in this context. For the treatment of sequelae in the course of Covid-19 disease, the compound has already passed through clinical phase 1 and a Phase 2/3 trial is commencing imminently. Studies are also planned for other indications, such as acute myocarditis and diastolic heart failure. The biotech company relies on a highly concentrated dose of cannabidiol for its active ingredient, ensuring that it is highly effective despite being taken orally. Pre-clinical studies show significant effects on diseased heart tissue. Cardiovascular complications are frequent consequences of severe courses in connection with Covid-19 and lead to many deaths independently of the pandemic.
Cardiol Therapeutics has also developed a commercial CBD preparation in addition to CardiolRx™. It is distinguished by its remarkable purity and freedom from THC. These preparations are particularly popular with elderly patients. With this second pillar, the biotech company now wants to take off on the stock market. Only recently, Cardiol Therapeutics announced that it has submitted its application to be listed on the Nasdaq, subject to the approval of the Nasdaq and the satisfaction of all applicable listing criteria and requirements. At the same time, the Company succeeded in raising an additional USD 10 million in capital through subscription rights. Cardiol Therapeutics thus has financial leeway and is unlikely to raise additional capital in the near future. The listing on Nasdaq should also ensure that the company's relative undervaluation compared to other biotech companies becomes even more visible on the market. A few weeks ago, the biotech company GW Pharmaceuticals, which also uses active ingredients from the cannabis plant, was acquired in the USA for more than USD 7 billion. Cardiol Therapeutics' market capitalization is just over USD 100 million.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.